INVESTINGAbbVie Shares Climb After Adjusted Profit Beats Analyst ViewsBy Tony OwusuJul 31, 2020 9:47 AM EDT
PRESS RELEASESAbbVie Announces Positive Phase 3 Data For Atogepant In Migraine PreventionBy PR NewswireJul 29, 2020 8:45 AM EDT
PRESS RELEASESFDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label For The Treatment Of Pediatric Patients With SpasticityBy PR NewswireJul 9, 2020 6:32 PM EDT
PRESS RELEASESAbbVie To Host Second-Quarter 2020 Earnings Conference CallBy PR NewswireJul 7, 2020 8:00 AM EDT
PRESS RELEASESAllergan, An AbbVie Company, And Molecular Partners Receive Complete Response Letter From FDA On Biologics License Application For Abicipar PegolBy PR NewswireJun 26, 2020 1:15 AM EDT
PRESS RELEASESAlector Announces Publication Of Preclinical And Phase 1 Data Validating Potential Of AL002, A TREM2 Activating Antibody For The Treatment Of Alzheimer's Disease, In The Journal Of Experimental MedicineBy GlobeNewswireJun 25, 2020 9:00 AM EDT
PRESS RELEASESIMBRUVICA® (ibrutinib) Seeks To Expand U.S. Label With Long-Term Data In Waldenström's Macroglobulinemia (WM)By PR NewswireJun 23, 2020 7:30 AM EDT
PRESS RELEASESFDA Accepts Supplemental Biologics License Application (sBLA) For BOTOX® (onabotulinumtoxinA) For The Treatment Of Pediatric Patients With Neurogenic Detrusor OveractivityBy PR NewswireJun 22, 2020 8:00 AM EDT
PRESS RELEASESFDA Approves JUVÉDERM® VOLUMA™ XC For Enhancement Of The Chin RegionBy PR NewswireJun 15, 2020 8:15 AM EDT
PRESS RELEASESAbbVie To Showcase 27 Studies At The Virtual 2020 Annual Scientific Meeting Of The American Headache SocietyBy PR NewswireJun 15, 2020 8:00 AM EDT
PRESS RELEASESAbbVie Recommends Shareholders Reject TRC Capital's "Mini-Tender" OfferBy PR NewswireJun 12, 2020 4:45 PM EDT
PRESS RELEASESAbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates Of Complete Skin Clearance Versus COSENTYX® (secukinumab) At 52 WeeksBy PR NewswireJun 12, 2020 3:02 PM EDT
PRESS RELEASESNovel Antibody Drug Conjugate ABBV-3373 Shows Improvement In Disease Activity In Phase 2a Study Of Patients With Rheumatoid ArthritisBy PR NewswireJun 10, 2020 8:15 AM EDT
INVESTINGAbbVie and Genmab Ink $4 Billion Cancer-Treatment PactBy M. Corey GoldmanJun 10, 2020 10:18 AM EDT
PRESS RELEASESAbbVie And Genmab Announce Broad Oncology CollaborationBy PR NewswireJun 10, 2020 6:00 AM EDT
PRESS RELEASESAbbVie, Harbour BioMed, Utrecht University And Erasmus Medical Center Announce Collaboration To Develop Monoclonal Antibody Therapy To Prevent And Treat COVID-19By Business WireJun 5, 2020 6:00 AM EDT
PRESS RELEASESAbbVie, Harbour BioMed, Utrecht University And Erasmus Medical Center Announce Collaboration To Develop Monoclonal Antibody Therapy To Prevent And Treat COVID-19By PR NewswireJun 5, 2020 6:00 AM EDT
PRESS RELEASESDr. Keshav K. Singh Joins Allergan Aesthetics Science Of Aging(SM) FacultyBy PR NewswireJun 4, 2020 7:00 AM EDT
